Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
Structure Therapeutics published Phase 2b ACCESS trial data for aleniglipron in Nature Medicine, highlighting dose-dependent weight loss up to 16.2% in the open-label extension. The data demonstrates a favorable tolerability profile with a low 10.4% discontinuation rate and suggests patients can successfully restart or up-titrate dosing after interruptions without significant recurrence of vomiting.
Key figures
- Drug Name
- aleniglipron
- Phase Of Trial
- Phase 2b
- Phase 3 start
- Q3 2026
- Starting dose mg
- 2.5
- Max weight loss pct
- 16.2%
- Discontinuation rate pct
- 10.4%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.